Carteolol; Mechanism, Uses, Contraindications, Dosage, Side effects, Interaction

Varenicline








User Review


5
(5 votes)


Carteolol is a synthetic quinolinone derivative and nonselective beta-adrenoceptor blocking agent with anti-glaucoma activity. Upon topical administration to the eye, carteolol decreases aqueous humor production, thereby reducing intraocular pressure (IOP).A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-anginal agent, an antihypertensive agent, and an antiglaucoma agent.

Carteolol is only found in individuals that have used or taken this drug. It is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-anginal agent, an antihypertensive agent, and an antiglaucoma agent. The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.

Mechanism of Action of Carteolol

The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade. Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Indications of Carteolol

  • Increased intraocular pressure
  • Treatment of intraocular hypertension and chronic open-angle glaucoma
  • Lowering of intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension

Dosage of Carteolol

Strengths: 1%

Intraocular Hypertension
  • One drop in the affected eye(s) twice a day
Glaucoma (Open Angle)
  • One drop in the affected eye(s) twice a day

……………….Details coming soon

References

  1. https://pubchem.ncbi.nlm.nih.gov

 

Carteolol

Print Friendly, PDF & Email

Sharing to Spread to the World

Leave a Reply

Your email address will not be published.